Drugs / BC2027
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07368478 | Nov 2025 → Dec 2027 expected | high grade malignant neoplasm | Biocity Biopharmaceutics Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BC2027 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07368478 ↗ |
| Route | Intravenous | “Administered via intravenous (IV) infusion” NCT07368478 ↗ |